Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。

サイズ 価格 在庫  
USD 233 あり
USD 138 あり
USD 214 あり
USD 466 あり
USD 1222 あり

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。
靶点
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NEXP[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe1xsDPxE1? M{jvOVQ5yqCq M{PPXoJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? MlvWNlY{PTB3NkW=
NP69 M3HuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPUSZloUUN3ME2zNU43QcLzMj61OEDPxE1? NGO0dGYzPjJ3MkW3OS=>
NP460 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW5SGRKSzVyPUKyMlg2yrFzLkG4JO69VQ>? NV3C[Jg3OjZ{NUK1O|U>
C666-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGSyUoJKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? MmHtNlYzPTJ3N{W=
C666-1 M3fUeWNmdGxiVnnhZoltcXS7IFHzd4F6 Mm\oNVAhyrWP NEjvVWc1QCCq MnnrSG1UVw>? M1HsUJNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= NWjPb4g4OjZ{NUK1O|U>
C666-1  NUPvS201TnWwY4Tpc44hSXO|YYm= M2\LNFExKML3TR?= M3vmdFI1KGh? NYLCZ2tjTE2VTx?= Mm[1ZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z MoPFNlYzPTJ3N{W=
C666-1 MXrBdI9xfG:|aYOgRZN{[Xl? M3Sye|ExKML3TR?= NWT5OZhJPDhxN{KgbC=> M1HsbWROW09? NIDTd3R{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MUmyOlI2OjV5NR?=
A549 M1PPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j0cVI1KGh? NYPPS|dmUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= NEGwfGczPjF{NUKzNC=>
A549-NTC NVy0ZZRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[xO|I1KGh? MV;JR|UxRTF7LkSyJOKyKDFwOU[g{txO NV7kflB2OjZzMkWyN|A>
A549-920 MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe4cZhrOjRiaB?= MlnPTWM2OD1|Mz64OUDDuSB2Lki0JO69VQ>? MkfLNlYyOjV{M{C=
CRL-5908 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu5dIUzPCCq MoqzTWM2OD1|OD63NUDDuSB{LkSzJO69VQ>? M1nkcVI3OTJ3MkOw
L6 NU[wTmw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPYS5U2OTEEoN88UeKh M2jiT|I1NzR6L{eyJIg> MVzEUXNQ MnnYbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v Mlf4NlU5PzF5OUS=
C2C12 M3nCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxNOKh|ryPwrC= NI\tVZgzPC92OD:3NkBp Ml;SSG1UVw>? MXLpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44> M3nCXFI2QDdzN{m0
MCF-7  M1XTbGZ2dmO2aX;uJGF{e2G7 MnfZNVDDqM7:TR?= MmfwSG1UVw>? MljnbY5pcWKrdIOgZ5lkdGmwIFSxJIFv\CCGaXPlduKh MnPRNlU4ODJ5MEO=
DU4475  M4rSW2Z2dmO2aX;uJGF{e2G7 NWXWTVJJPS9zMD:yNEDPxE1? MYWyOOKhcA>? M{HoR4Rwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> MYGyOVU1PzF5NB?=
SMMC-7721 NF\IdYJHfW6ldHnvckBCe3OjeR?= NXLwbml{OTBizszN MY[0PEBp NV3rOVBqTE2VTx?= M4C2WYNifXOnczDEUmEhTFOEIHThcYFo\Q>? NFvE[XEzPTV2NEO2NS=>
SMMC-7721 MXfGeY5kfGmxbjDBd5NigQ>? MWmxNEDPxE1? NIfPSHE1QCCq M1zjNGROW09? NFHRPHVqdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKh MnTVNlU2PDR|NkG=
SMMC-7721 MWHGeY5kfGmxbjDBd5NigQ>? MonHNVAh|ryP NFnwSHI1QCCq NXe0[|V4TE2VTx?= MnzsbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> NVfG[5Z2OjV3NESzOlE>
SMMC-7721 MVjGeY5kfGmxbjDBd5NigQ>? NEfafpEyOCEQvF2= MX2zOkBp NEX5eXJFVVOR M{O3doNifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 M3;5elI2PTR2M{[x
MCF-7 NXnQSplvTnWwY4Tpc44hSXO|YYm= M3TaWlExyqEQvF2= MUewMVI1KGh? NV\xNHlzcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx NW[wT4lNOjV2OEKzO|M>
OVCAR10 Mne1SpVv[3Srb36gRZN{[Xl? M4HTXVExyqEQvF2= Ml3yNlFpyqB? MXLEUXNQ NIXKSXRqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ NFzvSVYzPTR{NkW0PC=>
NCI-H23 NGqwb5JHfW6ldHnvckBCe3OjeR?= MmL5NVDDqM7:TR?= Mmf2NlFpyqB? NYHQW5hHTE2VTx?= M4nv[olv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MX[yOVQzPjV2OB?=
A2780 MkHNSpVv[3Srb36gRZN{[Xl? MUmxNOKh|ryP NITS[4EzOWkEoB?= MXzEUXNQ M4DxV4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> NXH3UIExOjV2Mk[1OFg>
NCI-H23 MmLSSpVv[3Srb36gRZN{[Xl? MorNNVDDqM7:TR?= MV:yNYjDqA>? M1uz[GROW09? Mnv3[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= M1XLdlI2PDJ4NUS4
A2780 M1zXe2Z2dmO2aX;uJGF{e2G7 M3S2d|ExyqEQvF2= MUKyNYjDqA>? MWTEUXNQ MUfk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= NV\sbXhWOjV2Mk[1OFg>
HCT116  NYDXWldrTnWwY4Tpc44hSXO|YYm= NFvxR|AyOCEEtV2= NUm1OJNlOjRiaB?= MmHnZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 MYGyOVM5ODB3NR?=
MCF-10CA1a M3jtWGZ2dmO2aX;uJGF{e2G7 M2rUdlExyqEQvF2= M{[zVlQ5KGh? M1;xemROW09? M1e2RolvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? NGPOb5UzPTJ3N{eyPS=>
MCF-10A1  NF;jO3lHfW6ldHnvckBCe3OjeR?= MYixNOKh|ryP M1L6dVI1NzR6IHi= NEjMeZFFVVOR NXTCbXJ5cW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi NFrxVIQzPTJ3N{eyPS=>
MCF-10CA1a NGnLNpBHfW6ldHnvckBCe3OjeR?= NGrONoUyOMLizszN NVzKR|VTOjRiaB?= NVHJVYRPTE2VTx?= MWLk[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? NH;KU5EzPTJ3N{eyPS=>
MCF-10CA1a MXvGeY5kfGmxbjDBd5NigQ>? MoTQNVDDqM7:TR?= NV6zcJYxOjRiaB?= NVLzRYhCTE2VTx?= NYj0U41GcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MVyyOVI2Pzd{OR?=
SK-BR-7 NGXFTYlHfW6ldHnvckBCe3OjeR?= M4j0elExyqEQvF2= MmnRNlQhcA>? M{fo[mROW09? MkDabY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M2DkOVI2OjV5N{K5
SUM102PT MXTGeY5kfGmxbjDBd5NigQ>? NHTMOHEyOMLizszN M2T6NFI1KGh? MWrEUXNQ M3TJcolvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NWjZeGs2OjV{NUe3Nlk>
RAW 264.7 NUPiUYFGTnWwY4Tpc44hSXO|YYm= MoH6NVDDqM7:TR?= MojZN|AhdWmw NYHSZmNTeHKndnXueJMhfGinIIC1N{Bz\WS3Y4Tpc44hcW5icnXzdI9ve2VidH:gUHBU NVO0fYhGOjVzN{K1OFc>
RAW 264.7 M1f2eGZ2dmO2aX;uJGF{e2G7 NHrQT|gyOMLizszN MnrZN|AhdWmw NH7iVGRz\WS3Y3XzJJRp\SCOUGOtZZVodWWwdHXkJJRp\SCQRj5OvmIhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5 NEO1bFUzPTF5MkW0Oy=>
RAW 264.7 M4\oUGZ2dmO2aX;uJGF{e2G7 Mmj6NVDDqM7:TR?= NW\wXIduOzBibXnu NWHuUW9[cW6qaXLpeJMhVFCVLXnu[JVk\WRiTl:gdJJw\HWldHnvcuKh MYqyOVE4OjV2Nx?=
MCF7  Mlv2R4VtdCCYaXHibYxqfHliQYPzZZk> M3jYdVIvPSEEtV2= MYW1JIQ> M4CybmROW09? NHLleJB{\W6|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u MXSyOVA5PTlyMh?=
MCF7  MnHaSpVv[3Srb36gRZN{[Xl? NVfVZ3ZZOi53INM1US=> MkG0OFghcA>? NYLHdWRbTE2VTx?= MVzk[YNz\WG|ZYOgeIhmKGixbX;sc4dwfXNiRGPCJJJmeGGrcjDmdoVyfWWwY3nldy=> MnfWNlUxQDV7MEK=
ACHN M3nrZWNmdGxiVnnhZoltcXS7IFHzd4F6 Mn\RNE42NTFyIN88US=> M1TOR|AuPiCm NEH2NZdFVVOR NFG4WlVqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MX6yOVA3Pzd6Nx?=
Caki-2 Mm\4R4VtdCCYaXHibYxqfHliQYPzZZk> NUDIXlh3OC53LUGwJO69VQ>? MUKwMVYh\A>? MXXEUXNQ M{LsTIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEn3ZoUzPTB4N{e4Oy=>
A498 M4Ta[mNmdGxiVnnhZoltcXS7IFHzd4F6 Mn;UNE42NTFyIN88US=> MnexNE03KGR? MVTEUXNQ M4ftWIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF3pT4gzPTB4N{e4Oy=>
115 NEjYVpBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{XZdVAvPS1zMDFOwG0> MmTqNE03KGR? NW\JXYxsTE2VTx?= NX7Rbol6cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUGyOVA3Pzd6Nx?=
117 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3rUc|AvPS1zMDFOwG0> Mn;LNE03KGR? MkHxSG1UVw>? MmPxbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MV2yOVA3Pzd6Nx?=
ACHN NWLBNGNSTnWwY4Tpc44hSXO|YYm= NHrXdoIxNjVxMT:1JO69VQ>? Mo\3OFghcA>? NXLjcZBqTE2VTx?= NG\KXXVt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NYrYc|hmOjVyNke3PFc>
Caki-2 MXzGeY5kfGmxbjDBd5NigQ>? NX\XUottOC53L{GvOUDPxE1? M3\2PFQ5KGh? NUG5XYZkTE2VTx?= MYPs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MXuyOVA3Pzd6Nx?=
A498 NUnDUpA2TnWwY4Tpc44hSXO|YYm= MVqwMlUwOS93IN88US=> M2Dnc|Q5KGh? NV\aTpBZTE2VTx?= MlHQcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NGHnUnIzPTB4N{e4Oy=>
115 NH3Lfm9HfW6ldHnvckBCe3OjeR?= M2nJdVAvPS9zL{Wg{txO M2nhflQ5KGh? NEH0dVNFVVOR M4n0XYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MnvDNlUxPjd5OEe=
ACHN M2LmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD5OUDPxE1? MkL5OFghcA>? NVH6TJozTE2VTx?= NFH5bHBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NIqxem8zPTB4N{e4Oy=>
Caki-2 NHHRTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm1JO69VQ>? MWi0PEBp NIjweHVFVVOR NH7CcWxqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> M33JflI2ODZ5N{i3
A498 M3zMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j5TFUh|ryP MVe0PEBp M{LBS2ROW09? M4Kw[Ilv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NFTabFMzPTB4N{e4Oy=>
115 NIXxbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEOzc4I2KM7:TR?= MVS0PEBp MVTEUXNQ MYXpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NI\DTlAzPTB4N{e4Oy=>
ACHN MVjGeY5kfGmxbjDBd5NigQ>? NH\ESJo2KM7:TR?= M2LPcVQ5KGh? NYnBRYc2TE2VTx?= MXHpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NWjT[5NPOjVyNke3PFc>
Caki-2 M{H5T2Z2dmO2aX;uJGF{e2G7 NU\sOlZlPSEQvF2= M1qz[VQ5KGh? MV7EUXNQ M2XxXolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M{nsPVI2ODZ5N{i3
A498 M4XRTmZ2dmO2aX;uJGF{e2G7 M3z2TlUh|ryP NIiwPW01QCCq M4HXbmROW09? MX;pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NVX2bFBoOjVyNke3PFc>
115 NEP1ZlFHfW6ldHnvckBCe3OjeR?= M2XVUlUh|ryP NW\Db2JbPDhiaB?= NUC2bWU4TE2VTx?= MnLlbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NHfBbFkzPTB4N{e4Oy=>
MOLM-13 MUnGeY5kfGmxbjDBd5NigQ>? NWTielJLPsLizszN MlzRNE05KGh? NWT1eZlxTE2VTx?= NXPoUWlQcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdFU{NCCPRF2yMEBxOjFiYX7kJIFk\XS7bHH0[YQheDV| M2PoRVI1QDh3MEiy
MOLM-13 M{Pye2Z2dmO2aX;uJGF{e2G7 NFr0W3E3yqEQvF2= NF:z[lM3KGh? NEHl[ZhFVVOR MXXlcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly NEHoN2gzPDh6NUC4Ni=>
HepG2 Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\mO|IhcA>? NF3RbFZFVVOR MX7JR|UxRTN3Lki2JOKyKDJwOTFOwG0> NH7VcW0zPDh6NEiwPS=>
HepG2/As NEO2fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly2O|IhcA>? MnrjSG1UVw>? NXmx[|REUUN3ME22PE4yOyEEsTC5MlYh|ryP M3X6WVI1QDh2OEC5
SMMC7721 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjXc4o4OiCq MkG0SG1UVw>? NYmzXXF3UUN3ME2zNU4zQCEEsTC0MlIh|ryP M3zDWFI1QDh2OEC5
SMMC7721/Ac NV\3WG5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W4elczKGh? NVnLdGVVTE2VTx?= MX\JR|UxRTV3LkKxJOKyKDVwMEOg{txO NGiwXVEzPDh6NEiwPS=>
Huh-7 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;JTVczKGh? MknrSG1UVw>? MVHJR|UxRTN|Lkm2JOKyKDNwOTFOwG0> MWeyOFg5PDhyOR?=
Hep3B NFPpUm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCyO|IhcA>? NVrLN|F2TE2VTx?= NV2ySVh6UUN3ME2yNE4yQCEEsTCxMlg1KM7:TR?= NXOzdmF6OjR6OES4NFk>
HepG2 NULpWlJ3SXCxcITvd4l{KEG|c3H5 MX3pcoR2[2W|IHHwc5B1d3Orcx?= MXiyOFg5PDhyOR?=
SMMC7721 MlWzRZBweHSxc3nzJGF{e2G7 MkfPbY5lfWOnczDhdI9xfG:|aYO= MlTLNlQ5QDR6MEm=
Huh-7 MUHBdI9xfG:|aYOgRZN{[Xl? NXTIV3k4cW6mdXPld{BieG:ydH;zbZM> MoTlNlQ5QDR6MEm=
Hep3B M3LwS2Fxd3C2b4Ppd{BCe3OjeR?= NVfGeYdNcW6mdXPld{BieG:ydH;zbZM> M3PibFI1QDh2OEC5
U2OS  NF3Tc|ZHfW6ldHnvckBCe3OjeR?= NGPqb4kzOCEQvF2= Mk\2NlQhcA>? NFzrT2dqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCEQ1yyRVEtKEKFTGjMxsBidmSEQ1zX NYLJbld4OjR6NkeyOVk>
AML2 M4fXfmFxd3C2b4Ppd{BCe3OjeR?= MnnRNk8yOCEQvF2= NGjKb44zPC92ODDo MXLpcoR2[2W|IHHwc5B1d3Orcx?= NYT2T5VvOjR4NUm3OFk>
MOML13 NUXPdWdjSXCxcITvd4l{KEG|c3H5 MmLXNk8yOCEQvF2= MYOyOE81QCCq MlXBbY5lfWOnczDhdI9xfG:|aYO= NF25[GMzPDZ3OUe0PS=>
AML2 MoiySpVv[3Srb36gRZN{[Xl? MVyxNO69VQ>? MYOyM|QhcA>? M4H6dIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz MmTSNlQ3PTl5NEm=
AML3 NI\BblVHfW6ldHnvckBCe3OjeR?= NHnjZokyOM7:TR?= MoW1Nk81KGh? NYjvUY5HcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> MkHnNlQ3PTl5NEm=
MOML13 MYrGeY5kfGmxbjDBd5NigQ>? NFXPXYEyOM7:TR?= MXiyM|QhcA>? MVTpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NWDie4tZOjR4NUm3OFk>
BeWo NFq0dI9HfW6ldHnvckBCe3OjeR?= NUjTUGx5OzBiwsXN MVSyOEBp MXjpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= M1Lx[|I1PDl6MUW0
BeWo NUTzVnYySXCxcITvd4l{KEG|c3H5 MWWzNEDDvU1? NGfJVmozPCCq MnL3bY5kemWjc3XzJIFxd3C2b4Ppdy=> NVjqcZU3OjR2OUixOVQ>
OCI NYfkV|FFTnWwY4Tpc44hSXO|YYm= MV2xNEDPxE1? NUTYSVN2OjRiaB?= M1Px[pVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NH;0dG4zPDR5M{W2Ni=>
MOLM NXuz[YZITnWwY4Tpc44hSXO|YYm= MVWxNEDPxE1? M4nZfFI1KGh? M4DDd5VxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= NYe2Tnh6OjR2N{O1OlI>
U2OS  NH[wTY1HfW6ldHnvckBCe3OjeR?= NYXEXHV{OjBizszN NH63PYMzPCCq MnrDbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? M2nYN|I1OzZ4MEC3
RKO NV[yeXpvTnWwY4Tpc44hSXO|YYm= MkLINlAh|ryP NFvDZnEzPCCq M4jHfolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? M{i5SFI1OzZ4MEC3
U2OS  NYWxdoc1TnWwY4Tpc44hSXO|YYm= NGLI[2IzOCEQvF2= NV;Efld3OjRiaB?= M3Hieolv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u MnzXNlQ{PjZyMEe=
RKO M1vnZWZ2dmO2aX;uJGF{e2G7 NGe1b4MzOCEQvF2= Ml3GNlQhcA>? NHe4d3lqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> MUmyOFM3PjByNx?=
SMMC-7721  NVyy[nB6S2WubDDWbYFjcWyrdImgRZN{[Xl? MYWxMlI2NTJyIN88US=> M2TqXFI1NzR6L{eyJIg> MWrEUXNQ MVPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MlPmNlQzQDZ|MUK=
HuH-7 MUnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWCxMlI2NTJyIN88US=> Ml21NlQwPDhxN{KgbC=> NVL3R3p3TE2VTx?= MXnpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MUmyOFI5PjNzMh?=
SMMC-7721  NX;SeIo2SXCxcITvd4l{KEG|c3H5 MVeyNEDPxE1? M3fEN|Q5KGh? MoHHSG1UVw>? NWqyfmRpcW6mdXPld{BieG:ydH;zbZM> MkPyNlQzQDZ|MUK=
HuH-7 M1\Ve2Fxd3C2b4Ppd{BCe3OjeR?= NWDjVFZWOjBizszN NFzQfIM1QCCq M{naZ2ROW09? MYLpcoR2[2W|IHHwc5B1d3Orcx?= NFyxXGgzPDJ6NkOxNi=>
SMMC-7721  NGLqNGRHfW6ldHnvckBCe3OjeR?= MWOxNEDPxE1? NH:3cXE{PiCq NWq0OFBWTE2VTx?= Mm\C[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MlLPNlQzQDZ|MUK=
HuH-7 MX3GeY5kfGmxbjDBd5NigQ>? NFfyfpQyOCEQvF2= NULnUVNqOzZiaB?= NULpZ20{TE2VTx?= M1\xOIRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ M3\3UVI1Ojh4M{Gy
AT2 M2DrW2Z2dmO2aX;uJGF{e2G7 M3LBUVUwOTBizszN MYjs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NHfse5gzPDJ2MEKwNy=>
REH NFfOc3RHfW6ldHnvckBCe3OjeR?= MX61M|ExKM7:TR?= MmjBcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? M3m0dVI1OjRyMkCz
UoCB6 M1u5XmZ2dmO2aX;uJGF{e2G7 M3PmWVUwOTBizszN NFfYO5lt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NGK4WZIzPDJ2MEKwNy=>
AT2 MmnsR4VtdCCYaXHibYxqfHliQYPzZZk> NXfIVYtQOC1{NTFOwG0> NEntNWRqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M1HHOFI1OjRyMkCz
REH NISwelBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M17NZVAuOjVizszN NYDibpdNcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MY[yOFI1ODJyMx?=
UoCB6 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUTTZotKOC1{NTFOwG0> NGHhdVlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MWiyOFI1ODJyMx?=
A2780 NEjRc|lHfW6ldHnvckBCe3OjeR?= NX3tVYpzPS9zMD:yNEDPxE1? MVqyOEBp MnPueZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NGTFN28zPDF|NkG0Oy=>
H460 NWmzOWZPTnWwY4Tpc44hSXO|YYm= NILJ[|g2NzFyL{KwJO69VQ>? M2jI[VI1KGh? NXq5bpJKfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= M2TYT|I1OTN4MUS3
Lovo  MYDGeY5kfGmxbjDBd5NigQ>? NETNTYE2NzFyL{KwJO69VQ>? MkHtNlQhcA>? MnnLeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? M1LrRVI1OTN4MUS3
A2780 NI[4T4FCeG:ydH;zbZMhSXO|YYm= NVLESYJvPS9zMD:yNEDPxE1? NV7zVYwyOjRiaB?= NXSyXVhs\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NVfsOVd6OjRzM{[xOFc>
H460 MkjoRZBweHSxc3nzJGF{e2G7 MoHsOU8yOC9{MDFOwG0> NYGzWZA3OjRiaB?= MmG0[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> M3;uU|I1OTN4MUS3
Lovo  MYLBdI9xfG:|aYOgRZN{[Xl? NXjENWd7PS9zMD:yNEDPxE1? M1XwdFI1KGh? M2e3NIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MknXNlQyOzZzNEe=

... Click to View More Cell Line Experimental Data

In vivo試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

プロトコル(参考用のみ)

キナーゼアッセイ:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞アッセイ:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物実験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water <1 mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2信号経路図

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID